Myriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
The goals of the study are three-fold: 1) to create an online registry of individuals consenting to a prospective follow up after having been tested with a pan-cancer panel test such as Myriad's myRisk™ Hereditary Cancer; 2) to provide infrastructure for the curation of specific genetic variants detected; and 3) to facilitate additional studies to characterize the significance of the genetic mutations. Myriad will contribute thousands of genetic mutations and its scientific expertise gained from having tested over 1.3 million patients for hereditary cancer risk.
"We look forward to collaborating with leading cancer centers to help end preventable hereditary cancers. Myriad's contribution of thousands of genetic mutations to the PROMPT study will help make this goal a reality by ensuring that researchers have access to critical, potentially life-saving information," said
This announcement continues Myriad's long-standing commitment to research collaborations. Myriad currently is engaged in scientific collaborations with more than 50 academic research institutions to help advance medical and scientific knowledge and healthcare overall. For more information visit: www.myriad.com/responsibility/research-collaborations/.
About the Prospective Registry of Multiplex Testing (PROMPT)
The PROMPT registry is a database that will include patients identified with deleterious or suspected deleterious mutations in any of the cancer susceptibility genes targeted in this research study. Individuals will be offered the opportunity to join the registry by participating in a process of informed consent. The study's Principal Investigators are
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's participation in the PROMPT research study; the goals and anticipated outcomes of the research study; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the
governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside
CONTACT: Media Contact:
Ron Rogers(801) 584-3065 email@example.com Investor Contact: Scott Gleason(801) 584-1143 firstname.lastname@example.org
News Provided by Acquire Media